v3.26.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Cash flows from operating activities:    
Net loss $ (20,400) $ (19,976)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 387 309
Stock-based compensation 1,003 1,017
Non-cash lease expense 74 153
Gain on derecognition of contract liabilities (335)
Changes in operating assets and liabilities:    
R&D tax credit incentive receivable 349 (411)
Prepaid expenses and other assets 14 1,062
Accounts payable 9 174
Accrued compensation expenses (46) 14
Accrued expenses 324 57
Net cash used in operating activities (18,621) (17,601)
Cash flows from investing activities:    
Purchases of property and equipment (102) (899)
Net cash used in investing activities (102) (899)
Cash flows from financing activities:    
Issuance of common stock to related party in connection with 2025 Private Sales Transactions, net 12,589 2,593
Issuance of common stock in connection with 2026 Registered Direct Offering, net 2,174
Issuance of common stock to related party in connection with 2026 Private Placement, net 1,997
Exercise of stock options 123
Gross proceeds from insurance premium loan 355
Payments on insurance premium loan (249) (237)
Net issuance costs in connection with the Sales Agreement (28)
Net cash provided by financing activities 16,634 2,683
Effect of exchange rate changes on cash and cash equivalents 2 93
Net decrease in cash, cash equivalents and restricted cash (2,087) (15,724)
Cash, cash equivalents and restricted cash balance at beginning of period 17,570 19,690
Cash, cash equivalents and restricted cash balance at end of period 15,483 3,966
Cash paid during the period for:    
Income taxes 2 2
Non-cash investing and financing activities:    
Purchases of property and equipment in accounts payable and accrued expenses $ 271 $ 443